04BIOMATRIX TESTING
ATEC has direct experience with the development of new matrices, and offers quantitative assays for toxicology and efficacy studies. These models and assays are also relevant to preclinical drug development, e.g. for wound-healing.
In vitro assays include:
- cellular adhesion / migration
- cytotoxicity, viability and apoptosis
(see Cytotoxicity product sheet)
- angiogenesis (see Angiogenesis assays)
- differentiation (see Differentiation & Organoid
Development)
- changes in matrix structure and composition
In vivo models, with appropriate histological and biochemical assays, in a range of animal species include:
- skin-flap survival
- implants
- tissue engineering chamber (with various
progenitor cells & tissues; for further information
see Differentiation & Organoid Development)
- matrix injection
ATEC Ltd is an Australian tissue engineering company providing expert contract R&D and testing services to commercial and public-sector clients.
Based within the world-renowned Bernard O’Brien Institute for Microsurgery
in Melbourne, ATEC offers technical excellence, and access to uniquely productive biological models. |
These include in vitro and in vivo angiogenesis; cytotoxicity analyses;
matrix development and formulation testing; and a variety of unique
models for target tissue growth (including cardiac, pancreatic islet,
adipose, and liver) in proprietary tissue engineering chambers in small
and large animals. Stem cell isolation, propagation, and in vitro and
in vivo differentiation analyses complement these tissue engineering
models. Human organoid models in nude rats and mice are in
development, and ATEC is open to proposals for co-development. |
Download a PDF Fact Sheet Here
For further information, or to discuss your specific project needs, please contact:
Australian Tissue Engineering Centre Limited
ABN 42 112 321 310
Level 3
42 Fitzroy Street
Fitzroy Victoria 3065
P: + 613 9288 3499
F: + 613 9288 3535
AUSTRALIAN TISSUE ENGINEERING CENTRE ABN 42 112 321 310